NYKD.OL实时信号 | 通过Getagraph.com最大化利润

购买 5219 min ago

@ Kr.14.60

发出时间: 16 May 2024 @ 21:39

回报率: 0.48%

上一信号: May 16 - 18:29

上一信号: 出售

回报率: -0.48 %

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 22:25):

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases...

Stats
今日成交量	459 602
平均成交量	1.00M
市值	4.79B
EPS	Kr.-0.520 ( 2024-05-16 )
Last Dividend	Kr.0 ( N/A )
Next Dividend	Kr.0 ( N/A )
P/E	-11.28
ATR14	Kr.0.430 (2.93%)

音量相关性

長: 0.00 (neutral)

短: 0.00 (neutral)

Signal:(0) Neutral

Nykode Therapeutics AS 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nykode Therapeutics AS 相关性 - 货币/商品

0.00
( neutral )

Financial Reports:

No articles found.

Nykode Therapeutics AS Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.